PEDIATRICS Vol. 101 No. 1 January 1998, pp. 148-153
| |
ABSTRACT |
|---|
|
|
|---|
The American Academy of Pediatrics is committed to the use of maternal breast milk as the ideal source of nutrition for infant feeding. Even so, by 2 months of age, most infants in North America are formula-fed. Despite limited indications, the use of soy protein-based formula has nearly doubled during the past decade to achieve 25% of the market in the United States. Because an infant formula provides the largest, if not sole, source of nutrition for an extended interval, the nutritional adequacy of the formula must be confirmed and the indications for its use well understood. This statement updates the 1983 Committee on Nutrition review1 and contains some important recommendations on the appropriate use of soy protein-based formulas.
Although soy protein-based nutrition has been used during infancy
for centuries in the Orient, the first use of soy formula feeding in
this country was in 1909.2 In 1929, Hill and
Stuart3 proposed soy protein-based feeding for infants with
intolerance to cow milk-based feeding.
Before the 1960s, soy protein-based formulas used soy flour, which
imparted a tan color and nutty odor to the formula, and infants
consuming it often had diarrhea and excessive intestinal gas. These
features and symptoms were attributed to residual indigestible carbohydrates in the soy.4,5 Since the mid-1960s, a soy
protein isolate has been used, reducing these concerns and greatly
increasing acceptance of the product.
The isolated soy protein-based formulas currently on the market
are all free of cow milk-protein and lactose, and prepared so they that
provide 67 kcal/dL. All are iron-fortified and meet the vitamin,
mineral, and electrolyte specifications addressed in the 1976 guidelines from the American Academy of Pediatrics for feeding
full-term infants6 and established by the US Food and
Drug Administration.7
The protein is a soy isolate supplemented with
L-methionine, L-carnitine, and taurine to
provide protein at 2.45 to 3.1 g/100 kcal or 1.65 to 2.1 g/dL. The
harvested soybean is processed by removal of the hull to yield a pulp
that is then refined to soybean oil and soybean flake. The defatted
flakes are processed into soy flour, soy protein isolate, or soy
cotyledon fiber. Soy protein isolate is extracted in a slightly
alkaline solution and precipitated at the isoelectric point of 4.5 to
yield a purity of at least 90% soy protein on a dry
basis.8
Supplementation with L-methionine began by the early 1970s.
In 1979, Fomon et al9 demonstrated improved biological
quality of the protein with the addition of sulfur-containing amino
acids. Subsequent studies in 1986 demonstrated that at a protein intake of 1.8 g/100 kcal, methionine was required to improve nitrogen balance,
whereas at intakes of 2.2 and 2.6 g/100 kcal, methionine supplementation improved weight gain, urea nitrogen excretion, and
albumin synthesis.10 Before the routine supplementation of
soy protein formulas with methionine, infants with undiagnosed, untreated cystic fibrosis were particularly at risk for severe hypoalbuminemia and edema when fed soy proteins, a risk that remains in
soy, cow milk, and breastfed infants with cystic fibrosis until the
initiation of pancreatic enzyme therapy.11,12
Carnitine, which is required for the optimal mitochondrial oxidation of
long-chain fatty acids, is deficient in foods of plant origin and is
added to soy formula to the level in breast milk, as is taurine, an
amino acid that is abundant in human milk. Taurine functions as an
antioxidant and, along with glycine, is a major conjugate of bile acids
in early infancy.
The fat content of soy protein-based formulas is derived primarily from
vegetable oils. The quantity of specific fats varies by manufacturer
and is usually similar to those in the corresponding cow milk-based
formula. The fat content ranges from 5.3 to 5.5 g/100 kcal or 3.6 to
3.8 g/dL. The oils used include soy, palm, sunflower, olein, safflower,
and coconut.
Carbohydrate is provided lactose free, as corn starch, corn starch
hydrolysate, tapioca starch, or sucrose, with content ranging from 10.0 to 10.2 g/100 kcal or 6.7 to 6.9 g/dL. Polysaccharide, in the form of
supplemented soy fiber, has been added to one soy protein-based
formula.13
Until 1980, mineral absorption from soy formulas was erratic because of
poor stability of the suspensions and the presence of excessive soy
phytates in the formula.14 Not surprisingly, conflicting
results of studies addressing the adequacy of bone mineralization were
reported.15-17 With the present formulations, bone
mineralization, serum levels of calcium and phosphorus, and alkaline
phosphatase levels in full-term infants through 6 to 12 months of age
are equivalent to those seen with cow milk-based formulas.17-19 Because soy protein isolate formulas still
contain 1.5% phytates and up to 30% of the total phosphorus is
phytate-bound, the total phosphorus and calcium content of the formulas
is ~20% higher than in cow milk-based formula, while still
maintaining the mandated calcium to available phosphorus ratio (1.1 to
2.0:1).
The soy phytates and fiber oligosaccharides also bind iron and
zinc.20 All soy-based formulas thus are iron-fortified and have proved as effective as iron-fortified (12 mg/L) cow milk-based formulas in the prevention of iron deficiency in
infants.21,22 With radiolabeled zinc, the highest
absorption of zinc is from human milk (41%) and the lowest is from soy
formula (14%).23 All soy protein-based formulas thus are
zinc-fortified.20,23 In one infant, the phytates may have
interfered with the uptake of exogenous thyroid hormone, binding the T4
within the lumen, increasing fecal loss, and reducing the efficacy of
oral thyroid hormone.24
Early studies revealed that the full nutritional value of soybean
protein is achieved only after heat has been applied. Subsequent studies confirmed the presence of a number of heat-labile factors with
biological activity in soybean-based products. The most prominent of
these factors is a soybean protease inhibitor with the properties of an
antitrypsin, antichymotrypsin, and antielastin.25 Soybean protein isolate, as heated for infant formulas, removes 80% to 90% of
this protease inhibitor activity and renders it nutritionally irrelevant. There also are heat-stable factors that remain in the soy
protein isolate, including the low-molecular-weight fibers, phytates,
saponins, and phytoestrogens.
The phytoestrogens demonstrate physiologic activity in rodent models
and, per unit of body weight, the infant's potential intake of
phytoestrogen from isolated soy protein-based formula is higher than
that demonstrated to influence the menstrual cycle of
humans.26 Very limited human data to date, however, suggest that soy phytoestrogens have a low affinity for human postnatal estrogen receptors and low potency in bioassays.25 A number of studies are addressing this issue at this time.
In 1996, the American Academy of Pediatrics issued a statement on
aluminum toxicity in infants and children and discussed the relatively
high content of aluminum in soy-based formulas.27 Although
the aluminum content of human milk is 4 to 65 ng/mL, that of soy
protein-based formula is 600 to 1300 ng/mL.8,28-31 The
source of the aluminum is the mineral salts used in formula production.
Aluminum, which makes up 8% of the earth's crust as the third most
common element, has no known biological function in
humans.28 The toxicity of aluminum is traced to increased deposition in bone and in the central nervous system, particularly in
the presence of reduced renal function in preterm infants and children
with renal failure. Additional potential sources of aluminum include
total parenteral nutrition solutions, renal dialysis fluids, and
aluminum-containing antacids. Because aluminum competes with calcium
for absorption, increased amounts of dietary aluminum from isolated soy
protein-based formula may contribute to the reduced skeletal
mineralization (osteopenia) observed in preterm infants and infants
with intrauterine growth retardation.32 Term infants with
normal renal function do not seem to be at substantial risk for
aluminum toxicity from soy protein-based formulas.8
Numerous studies have documented normal growth and development in
term neonates fed methionine-supplemented isolated soy protein-based formulas.8,33-37 Average energy intakes in infants
receiving soy protein formulas also are equivalent to those achieved
with cow milk formula.8 The serum albumin concentration, as
a marker of nutritional adequacy, also is normal,8,10,34,38
and bone mineralization also is equivalent to that documented with cow milk-based formula.15-19 Additional studies confirm that
soy protein formulas do not interfere with the normal immune responses
to oral immunization with polio vaccine.39,40
Preterm infants who weighed from 1500 to 1800 g and were fed
methionine-supplemented soy protein-based formulas demonstrated significantly less weight gain, less length gain, and lower serum albumin levels than that achieved with cow milk-based
formulas.41 With lower birth weights, ie, <1500
g, data conflict; one study demonstrated equivalent growth and plasma
protein levels,42 whereas another demonstrated significant
reductions in both.43
All three studies of preterm infants agreed, however, that serum
phosphorus levels were lower in the preterm infants fed soy protein-based formula and, when measured, the alkaline phosphatase levels were higher.41,42 As anticipated from these
observations, the osteopenia of prematurity is reportedly increased in
low birth weight infants receiving soy protein-based
formulas.44,45 Even with supplemental calcium and vitamin
D, radiographic evidence of increased osteopenia was present in 32% of
125 preterm infants fed soy protein-based formula.45
When combined with concerns about aluminum toxicity, the failure to
achieve equivalent growth rates or albumin levels consistently and the
reduced bone mineralization lead to the conclusion that soy
protein-based formulas should not be fed to low birth weight preterm
infants. The newer cow milk protein-based formulas designed for preterm
infants are clearly superior.
When strict dietary lactose elimination is required in the
management of infants with galactosemia or primary lactase deficiency, the soy protein formulas are safe and cost-effective. Soy protein-based formulas with sucrose as the carbohydrate are contraindicated in
sucrase-isomaltase deficiency and in hereditary fructose intolerance.
Results of studies in animal models using a diabetes-prone rat
suggested an increased frequency of diabetes when ingesting a soybean
meal diet. However, when soy protein isolate or hydrolyzed soy protein
feedings were used, no significant increase in diabetes was noted. This
suggests that the factor contributing to the increased frequency of
diabetes in this animal model is not the soy protein present in infant
formulas.46
Because of the role of lactose-free soy protein-based formulas in
the management of long-term lactose restriction, a number of studies
have addressed the role of these formulas in the recovery from acute
infantile diarrhea complicated by transient lactase deficiency. After
immediate rehydration, most infants can be managed successfully with
continued breastfeeding or standard cow milk or soy
formula.47,48 In an extensive review,
Brown47 noted that the dietary failure rate of
lactose-containing formulas was 22%, whereas that of lactose-free
formulas was 12%. In a study comparing breast milk, cow milk-based
formula, and soy protein-based formula, no difference was found in the
rate of recovery from rotavirus or nonrotavirus diarrhea based on
nutritional therapy.49 Although not significant from the
perspective of nutritional compromise, the duration of diarrhea has
been reported to be shorter in infants receiving soy protein-based
formula.50,51 The duration of liquid stools may be reduced
further by adding additional soy polysaccharide fiber52 or
by resuming a mixed-staple diet.53
Any ingested large molecular weight protein is a potential antigen
to the intestinal immune system. In soy protein isolate, 90% of the
pulp-derived protein resides in two major heat-stable globulins:
Severe gastrointestinal reactions to soy protein formula have been
described for >30 years59 and encompass the full
gamut of disease seen with cow milk protein in infancy These dietary protein-induced syndromes of enteropathy and
enterocolitis, although clearly immunologic in origin, are not immunoglobulin E-mediated, reflecting instead an age-dependent transient soy protein hypersensitivity.74 Because of the
reported high frequency of infants sensitive to both cow milk and soy
antigens, soy protein-based formulas are not indicated in the
management of documented cow milk protein-induced enteropathy or
enterocolitis.
Recognizing that soy protein is antigenic does not mean that soy
protein is highly allergenic. To address immunoglobulin E (IgE)-mediated hypersensitivity to soy protein-based formula, three
types of studies have been performed. The first addresses the frequency
with which proven allergy develops in healthy infants fed cow milk- or
soy protein-based formulas. The second addresses the same question in
infants at high risk according to a family history of allergic
responses to dietary protein. The symptom is usually eczema, and the
high-risk history usually includes a family history of atopic disease
(eg, asthma, allergic rhinitis, or eczema). The third type of study
addresses the response of infants with proven cow milk allergy to
subsequent ingestion of soy protein-based formula. The problem with
these studies is with the definition of allergy, which included
fussiness, colic, emesis, a positive RAST antibody, and/or a positive
double-blind, placebo-controlled challenge.
In a prospective study of healthy infants fed breast milk, cow milk
formula, or soy-based formula, Halpern et al75
documented allergic responses to soy in 0.5% of infants and to cow
milk in 1.8%. This frequency is consistent with the summary by
Fomon76 that in 3 decades of study of soy-based formulas,
<1% of soy formula-fed infants had adverse reactions. In a national
survey of pediatric allergists, the occurrence of allergy to cow milk
was reported at 3.4%, whereas allergy to soy protein was reported to
be 1.1%.77 Two large studies of infants with atopic
dermatitis addressed the frequency with which a double-blind,
placebo-controlled challenge with soy protein was positive.
Sampson78 documented soy positivity in 5% of 204 patients,
whereas Businco et al79 implicated soy in 4% of 143 children.
Prospective studies of high-risk infants suggest that soy protein-based
formula has no relative value over cow milk formula in the prophylaxis
or prevention of allergic disease.80-84 Furthermore, the
use of soy protein-based formula during the first 3 months of age does
not reduce the frequency of positive antibody responses to cow milk
formula introduced later in infancy.85 When human milk
feeding is supplemented with soy formula in high-risk infants, the
anticipated frequency of eczema by 2 years of age is not significantly reduced.79,80,86,87 Interpretation of these data is
obscured by multiple alterations in the maternal diet and by
environmental stimuli. The issue of delay in allergic disease, as
opposed to the prevention of allergic disease, awaits the result of
long-term investigations. Fortunately, true anaphylaxis after soy
protein exposure has been reported only once.88 According
to the data now available, isolated soy protein-based formula has no
advantage over cow milk-based formula for supplementing the diet of a
breastfed infant.
Two studies documented the frequency of tolerance to soy protein in a
small number of children with documented allergy to cow milk protein as
defined by a positive skin test and positive double-blind,
placebo-controlled challenge. The rate of combined positivity to cow
milk and soy approximated 10%.89,90
Colicky discomfort, apparently abdominal in origin, is described
by the parents of 10% to 20% of infants during the first 3 months of
age.91 Although many factors have been implicated, parents frequently seek relief by changing infant formula. Although some calming benefit can be attributed to the sucrose92,93 and fiber content,13 controlled trials of cow milk and soy
protein-based formulas have not demonstrated a significant benefit from
soy.94,95 The value of parental counseling as to the cause
and duration of colic seems greater than the value of switching to soy
formula.96 Because most colicky behavior diminishes
spontaneously between 4 and 6 months of age, any intervention at that
time can be credited anecdotally.
![]()
BACKGROUND
Top
Abstract
Background
References
![]()
COMPOSITION OF ISOLATED SOY PROTEIN-BASED FORMULAS
![]()
SOY PROTEIN-BASED FORMULAS IN TERM INFANTS
![]()
SOY PROTEIN-BASED FORMULAS IN PRETERM INFANTS
![]()
USE IN DISORDERS OF CARBOHYDRATE METABOLISM
![]()
USE IN ACUTE DIARRHEA AND SECONDARY LACTASE DEFICIENCY
![]()
ANTIGENICITY OF SOY PROTEIN-BASED FORMULAS
-conglycin, with a molecular weight of 180 000, and glycinin, with
a molecular weight of 320 000. The former has three subunits, and the
latter has six.54 After enteric digestion, the number
of potential antigens generated at the mucosal surface is
enormous.55 As a result, the in vitro demonstration of
antigen-specific antibody can be difficult. The antigenicity of soy
protein, suspected since 1934,56 was documented in low-risk
infants by Eastham et al57 in 1982. Intrauterine
sensitization has been documented by demonstrating antigen-specific
antibody in human amniotic fluid.58
enteropathy, enterocolitis, and proctitis. Small-bowel injury, a reversible celiac-like villus injury that produces an enteropathy with
malabsorption, hypoalbuminemia, and failure to thrive, has been
documented in at least four studies.60-63 To date, those
afflicted have responded to the elimination of soy protein-based
formulas and are no longer sensitive by 5 years of age. Severe
enterocolitis manifested by bloody diarrhea, ulcerations, and
histologic features of acute and chronic inflammatory bowel disease
also has been well described in infants receiving soy protein-based
formulas.64-68 They respond quickly to elimination of the
soy formula and introduction of a hydrolyzed protein formula. Their
degree of sensitivity to soy protein during the first few years of age
can remain dramatic; thus, casual use of soy-based formula is to be
avoided.68,69 Most children, but not all, can resume soy
protein consumption safely after 5 years of age. In addition, up to
60% of infants with cow milk protein-induced enterocolitis also will
be equally sensitive to soy protein.68-70 It is theorized
that the intestinal mucosa damaged by cow milk allows increased uptake
and, therefore, increased immunologic response to the subsequent
antigen soy. Eosinophilic proctocolitis, a more benign variant of
enterocolitis, also has been reported in infants receiving soy
protein-based formula.70-73
![]()
ALLERGENICITY OF SOY PROTEIN-BASED FORMULAS
![]()
TREATMENT OF COLIC WITH SOY PROTEIN-BASED FORMULA
![]()
CONCLUSIONS AND RECOMMENDATIONS
COMMITTEE ON NUTRITION, 1996 TO 1997
William J. Klish, MD, Chair
Susan S. Baker, MD
William J. Cochran, MD
Carlos A. Flores, MD
Michael K. Georgieff, MD
Marc S. Jacobson, MD
Alan M. Lake, MD
LIAISON REPRESENTATIVES
Donna Blum
US Department of Agriculture
Suzanne S. Harris, PhD
International Life Sciences Institute
Van S. Hubbard, MD
National Institute of Diabetes & Digestive & Kidney Diseases
Ephraim Levin, MD
National Institute of Child Health & Human
Development
Ann Prendergast, RD, MPH
Maternal & Child Health Bureau
Alice E. Smith, MS, RD
American Dietetic Association
Elizabeth Yetley, PhD
Food and Drug Administration
Stanley Zlotkin, MD
Canadian Paediatric Society
AAP SECTION LIAISON
Ronald M. Lauer, MD
Section on Cardiology
| |
FOOTNOTES |
|---|
The recommendations in this statement do not indicate an exclusive course of treatment or serve as a standard of medical care. Variations, taking into account individual circumstances, may be appropriate.
| |
ABBREVIATIONS |
|---|
IgE, immunoglobulin E.
| |
REFERENCES |
|---|
|
|
|---|
another cause of the flat intestinal lesion.
Gastroenterology.
1972;
62:227-234 [Medline] The following policy statement is a revision:
This article has been cited by other articles:
![]() |
A. Andres, S. M. Donovan, T. B. Kuhlenschmidt, and M. S. Kuhlenschmidt Isoflavones at Concentrations Present in Soy Infant Formula Inhibit Rotavirus Infection in Vitro J. Nutr., September 1, 2007; 137(9): 2068 - 2073. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. E. Teitelbaum and J. P. Lagmay Familiarity of Pediatricians With Different Commercially Available Neonatal and Infant Formulas Clinical Pediatrics, June 1, 2007; 46(5): 418 - 423. [Abstract] [PDF] |
||||
![]() |
K. A.L. Tan, M. Walker, K. Morris, I. Greig, J. I. Mason, and R. M. Sharpe Infant feeding with soy formula milk: effects on puberty progression, reproductive function and testicular cell numbers in marmoset monkeys in adulthood Hum. Reprod., April 1, 2006; 21(4): 896 - 904. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. B. Lasekan, W. W. K. Koo, J. Walters, M. Neylan, and S. Luebbers Growth, tolerance and biochemical measures in healthy infants fed a partially hydrolyzed rice protein-based formula: a randomized, blinded, prospective trial. J. Am. Coll. Nutr., February 1, 2006; 25(1): 12 - 19. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Drenckpohl, J. Hocker, M. Shareef, R. Vegunta, and C. Colgan Adding Dietary Green Beans Resolves the Diarrhea Associated With Bowel Surgery in Neonates: A Case Study Nutr Clin Pract, December 1, 2005; 20(6): 674 - 677. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Huang, C. Wood, M. R. L'Abbe, G. S. Gilani, K. A. Cockell, and C. W. Xiao Soy Protein Isolate Increases Hepatic Thyroid Hormone Receptor Content and Inhibits Its Binding to Target Genes in Rats J. Nutr., July 1, 2005; 135(7): 1631 - 1635. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. K C Leung and J. F. Lemay Infantile colic: a review The Journal of the Royal Society for the Promotion of Health, July 1, 2004; 124(4): 162 - 166. [Abstract] [PDF] |
||||
![]() |
R. J. Merritt and B. H. Jenks Safety of Soy-Based Infant Formulas Containing Isoflavones: The Clinical Evidence J. Nutr., May 1, 2004; 134(5): 1220S - 1224S. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. S. Zeiger Food Allergen Avoidance in the Prevention of Food Allergy in Infants and Children Pediatrics, June 1, 2003; 111(6): 1662 - 1671. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Yonezawa, S. Nunomiya, M. Daigo, Y. Ogra, K. T. Suzuki, K. Enomoto, H. Nakagama, K. Yoshikawa, and M. Nagao Soy Protein Isolate Enhances Hepatic Copper Accumulation and Cell Damage in LEC Rats J. Nutr., May 1, 2003; 133(5): 1250 - 1254. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. A. Mendez, M. S. Anthony, and L. Arab Soy-Based Formulae and Infant Growth and Development: A Review J. Nutr., August 1, 2002; 132(8): 2127 - 2130. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. M. Sharpe, B. Martin, K. Morris, I. Greig, C. McKinnell, A. S. McNeilly, and M. Walker Infant feeding with soy formula milk: effects on the testis and on blood testosterone levels in marmoset monkeys during the period of neonatal testicular activity Hum. Reprod., July 1, 2002; 17(7): 1692 - 1703. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Yellayi, A. Naaz, M. A. Szewczykowski, T. Sato, J. A. Woods, J. Chang, M. Segre, C. D. Allred, W. G. Helferich, and P. S. Cooke The phytoestrogen genistein induces thymic and immune changes: A human health concern? PNAS, May 28, 2002; 99(11): 7616 - 7621. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. M. Badger, M. J. J. Ronis, R. Hakkak, J. C. Rowlands, and S. Korourian The Health Consequences of Early Soy Consumption J. Nutr., March 1, 2002; 132(3): 559S - 565. [Abstract] [Full Text] [PDF] |
||||
![]() |
E RIVA, A FIOCCHI, L FIORI, and M GIOVANNINI Prevention and treatment of cow's milk allergy Arch. Dis. Child., January 1, 2001; 84(1): 89f - 89. [Full Text] |
||||
![]() |
Committee on Nutrition Hypoallergenic Infant Formulas Pediatrics, August 1, 2000; 106(2): 346 - 349. [Abstract] [Full Text] |
||||
![]() |
S. Levitzky and R. Cooper Infant Colic Syndrome--Maternal Fantasies of Aggression and Infanticide Clinical Pediatrics, July 1, 2000; 39(7): 395 - 400. [Abstract] [PDF] |
||||
![]() |
R. T. Hall and R. E. Carroll Infant Feeding Pediatr. Rev., June 1, 2000; 21(6): 191 - 200. [Full Text] |
||||
![]() |
F. P. Polack, N. Khan, and M. J. Maisels Changing Partners: The Dance of Infant Formula Changes Clinical Pediatrics, November 1, 1999; 38(12): 703 - 708. [Abstract] |